Jump to content or navigation.
Eranid Coordination of Research on illicit drugs Contact us

European Research Network on Illicit Drugs, ERANID, launched

May 7, 2013

Elisabetta Simeoni (Head of International Relations, DPA, Italy), Els van Gessele (Project Coordinator ERANID, ZonMw) and Giovanni Serpelloni (Head of DPA, Italy) during the press conference in Rome.

Sala Stampa Estera - Rome Today ERANID, the European Research Area Network on Illicit Drugs, a project funded by the European Union, has been launched. ERANID can be considered as a first fundamental step towards long-term co-operation in the field of scientific research on illicit drugs. The development of shared priorities for research on illicit drugs and the funding of joint research projects in this field are the main objectives of this project.

With the development of a Strategic Research Agenda, based on existing evidence and a common understanding of priorities, ERANID will increase the knowledge of both drug demand and supply issues and their complex relationship. The project operates mainly in the field of socio-economic sciences and humanities and aims to strengthen and widen the network of research programmes and participants. Closer co-operation amongst researchers of different European and other countries may lead to further development in research techniques and the effective evaluation of policy strategies and innovative programmes. Disseminating the results of the acquired knowledge will support policy decisions and actions.

The participating countries are Belgium, France, Italy, the Netherlands, Portugal and the United Kingdom. The project, which will last for four years, will also collaborate closely with two important organisations: the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the Pompidou Group of the Council of Europe.
The coordinator of ERANID is ZonMw (The Netherlands). 

This month ERANID will start the development of a Strategic Research Agenda for which we will ask the co-operation of stakeholders.
To stay informed, sign up for our newsletter.